Skip to main content
Premium Trial:

Request an Annual Quote

Accelrys Q2 Sales Dip, But Profit Rises

NEW YORK (GenomeWeb News) - Accelrys yesterday said fiscal second-quarter 2008 revenues fell around 2 percent as R&D spending dropped around 13 percent and profit shot up 75 percent.
 
Total receipts for the three months ended Sept. 30, 2007, dipped to $19.7 million from $20.2 million year over year.
 
Second-quarter revenue was impacted by “reduced revenues from de-emphasized products” and was offset in part by “continued growth in the solutions and services surrounding the company’s scientific operating platform product line,” the company said.
 
Accelrys’ R&D spending decreased to $4.3 million from $4.9 million year over year.
 
The firm’s net income rose to $1.6 million from $935,000 in the year-ago period.
 
Accelrys said it had around $64.9 million in cash, cash equivalents, and marketable securities as of Sept. 30.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.